Ultime notizie per Longeveron (NASDAQ:LGVN) Azioni

Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Longeveron Inc

Biotech

News

Events

General

LGVN

Longeveron Announces Late Breaking Poster Presentation At Clinical Trials On Alzheimer's Disease Conference On Oct. 29

Longeveron Lomecel-B 5-Year Long-Term Transplant-Free Survival Data In HLHS Selected For Oral Presentation At Congenital Heart Surgeons' Society 51st Annual Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

<ul>
<li>On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential full traditional approval</li>
<li>Alignment with FDA on ELPIS II primary and secondary endpoints
<ul>
<li>Alignment with FDA on CMC and Potency Assay plan and requirements &nbsp;</li>
</ul>
</li>
</ul>

Longeveron Announces Type C Meeting With U.S. FDA Regarding Pathway to BLA for Lomecel-B In Hypoplastic Left Heart Syndrome

In the preceding three months, 4 analysts have released ratings for Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.0, along with a high estimate of $10.00 and a low estimate of $6.00. This current average has decreased by 23.4% from the previous average price target of $11.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1724770847_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Longeveron among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Okunewitch</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Longeveron. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Longeveron compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Longeveron's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Longeveron's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LGVN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Longeveron analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Longeveron: A Closer Look</h2>
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
<h3>Longeveron's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Longeveron displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 115.67%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Longeveron's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2545.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Longeveron's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -132.73%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -81.91%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.12, Longeveron adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Longeveron Stock

Maxim Group analyst Michael Okunewitch maintains Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and lowers the price target from $15 to $6.

Maxim Group Maintains Buy on Longeveron, Lowers Price Target to $6

Longeveron To Participate In H.C. Wainwright 26th Annual Global Investment Conference On September 10, 2024; Webcast Available On Company Website

Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(1.83) per share. This is a 31.46 percent increase over losses of $(2.67) per share from the same period last year. The company reported quarterly sales of $468.00 thousand which missed the analyst consensus estimate of $525.00 thousand by 10.86 percent. This is a 115.67 percent increase over sales of $217.00 thousand the same period last year.

Earnings

Earnings Misses

Longeveron Q2 2024 GAAP EPS $(1.83) Up From $(2.67) YoY, Sales $468.00K Miss $525.00K Estimate

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent080124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for the month of July 2024. Current prices and year-to-date performances are based on Aug. 1 and do not include dividends. April search results were not tracked.
1. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $539.92</li>
<li>52-Week Range: $138.80 to $278.97</li>
<li>Year-to-Date Return: -13.5%</li>
<li><a href="https://www.benzinga.com/news/earnings/23/02/30713474/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-january-where-do-spy-tesla-apple-and-ford">January</a>/<a href="https://www.benzinga.com/markets/penny-stocks/23/03/31137326/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-february-including-tesla-apple-and">February</a>/<a href="https://www.benzinga.com/markets/equities/24/04/38023764/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-march-where-do-tesla-nvidia-spy-and-re">March </a>Search Ranking: 1st/4th/2nd</li>
<li><a href="https://www.benzinga.com/exclusives/24/06/39234936/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-may-where-do-nvidia-tesla-gamestop-amc-ran">May</a>/<a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June </a>Search Ranking: 4th/4th</li>
</ul>
2. NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>Current Price: $107.80</li>
<li>52-Week Range: $39.23-$140.76</li>
<li>YTD Return: +117.7%</li>
<li>January/February/March Search Ranking: 3rd/1st/1st</li>
<li>May/June Search Ranking: 2nd/1st</li>
</ul>
3. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $539.90</li>
<li>52-Week Range: $401.22-$565.22</li>
<li>YTD Return: +13.6%</li>
<li>January/February/March Search Ranking: 2nd/2nd/3rd</li>
<li>May/June Search Ranking: 1st/3rd</li>
</ul>
Read Also: <a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In First Half 2024 – Where Do Nvidia, Tesla, Palantir, GameStop Rank?</a>
4. Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
<ul>
<li>Current Price: $131.34</li>
<li>52-Week Range: $93.12 to $227.30</li>
<li>YTD Return: -11.0%</li>
<li>January/February/March Search Ranking: 12th/14th/8th</li>
<li>May/June Search Ranking: 8th/9th</li>
</ul>
5. Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)
<ul>
<li>Current Price: $16.23</li>
<li>52-Week Range: $1.77 to $37.00</li>
<li>YTD Return: N/A (IPO in March)</li>
<li>January/February/March Search Ranking: Not in Top 20 in any</li>
<li>May/June Search Ranking: Not in Top 20 in either</li>
</ul>
6. Zapp Electric Vehicles Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>)
<ul>
<li>Current Price: $10.02</li>
<li>52-Week Range: $0.70 to $39.80</li>
<li>YTD Return: +89.5%</li>
<li>January/February/March Search Ranking: Not in Top 20 in any</li>
<li>May/June Search Ranking: Not in Top 20 in either</li>
</ul>
7. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $217.23</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>YTD Return: +12.8%</li>
<li>January/February/March Search Ranking: 5th/8th/4th</li>
<li>May/June Search Ranking: 6th/5th</li>
</ul>
8. Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
<ul>
<li>Current Price: $493.69</li>
<li>52-Week Range: $274.39 to $542.79</li>
<li>YTD Return: +39.6%</li>
<li>January/February/March Search Ranking: Not in Top 20/6th/Not in Top 20</li>
<li>May/June Search Ranking: Not in Top 20 in either</li>
</ul>
9. CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)
<ul>
<li>Current Price: $221.90</li>
<li>52-Week Range: $140.52 to $398.33</li>
<li>YTD Return: -13.1%</li>
<li>January/February/March Search Ranking: Not in Top 20 in any</li>
<li>May/June Search Ranking: Not in Top 20/16th</li>
</ul>
10. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
<ul>
<li>Current Price: $182.08</li>
<li>52-Week Range: $118.35 to $201.20</li>
<li>YTD Return: +23.1%</li>
<li>January/February/March Search Ranking: 19th/7th/Not in Top 20</li>
<li>May/June Search Ranking: 13th/18th</li>
</ul>
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent080124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent080124&amp;t=be2bearmibe3na1">Benzinga Pro</a> in the first half of 2024:
11. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
12. SOBR Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>)
13. Inspire Veterinary Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>)
14. MIRA Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>)
15. Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
16. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
17. NuZee Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>)
18. Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>)
19. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
20. Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>)
Why It's Important: Tesla regained the top spot as the most searched ticker for the first time since January. The company reported <a href="https://www.benzinga.com/news/earnings/24/07/39918390/tesla-q2-earnings-highlights-revenue-beat-eps-miss-robotaxi-update-2024-growth-rate-to-be-notably-l">second-quarter financials results</a> in July and saw a surge in its share price.
One of the bigger stories in this top 20 tickers list is a name that's not on it: GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), The company ranked just outside the list cutoff at 21 for July, which comes after ranking second in June and 7th overall in the first half of 2024.
Serve Robotics saw increased interest from investors thanks to <a href="https://www.benzinga.com/news/24/07/39972757/serve-robotics-stock-continues-to-soar-whats-going-on">an ownership stake</a> in the company from Nvidia. Serve and Zapp Electric Vehicles were the main newcomers to the top 10 as names not in the top 20 in 2024.
Meta Platforms rejoined the top 10 for the first time since February, a move that comes as the stock typically doesn't even rank among the top 20 most-searched tickers on Benzinga Pro monthly. The company could also be a top stock in August after reporting quarterly financial results on July 31 and seeing its stock soar.
CrowdStrike hit its highest ranking for the year at ninth place, but it wasn't for good reasons. The cybersecurity company was behind an update that <a href="https://www.benzinga.com/news/24/07/39861744/microsoft-outage-what-states-services-companies-saw-the-blue-screen-of-death">took down Windows products </a>worldwide and hurt several major sectors including financials and airlines.
For the honorable mention names, Super Micro Computer saw a significant fall after ranking in the top five of the six months tracks and falling to 19th.
Palantir lost some momentum falling to 16th place, after enjoying several higher rankings earlier in the year and ranking 10th overall for the first half of 2024.
Ranking just outside the top 20 are two names to watch in the coming months. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) ranked 23rd. The stock has been volatile related to events around former President Donald Trump. With the 2024 election nearly three months away, the stock could gain increased attention.
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) ranked 22nd and just outside the top 20. The small-cap ETF could be gaining popularity with some level of rotation by investors from large-cap stocks into small-cap stocks. With a potential rate cut by the Federal Reserve in September, small cap stocks could be focus in the months ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39986280/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Shutterstock

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?

<a href="https://ipsearch.ipaustralia.gov.au/patents/2017213812" title="https://ipsearch.ipaustralia.gov.au/patents/2017213812">https://ipsearch.ipaustralia.gov.au/patents/2017213812</a>

Global

Longeveron Has Been Granted Australian Patent Number 2017213812 Titled "Mesenchymal Stem Cells As Vaccine Adjuvants And Methods For Using The Same".

Shares of Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) fell sharply during Monday's session after the company reported <a href="https://www.benzinga.com/quote/BMRC/earnings">worse-than-expected quarterly earnings.</a>
Bank of Marin reported quarterly earnings of 6 cents per share which missed the analyst consensus estimate of 18 cents per share. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Bank of Marin Bancorp shares dipped 10.8% to $19.92 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares climbed 128% to $2.8535.</li>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares climbed 117.8% to $0.9039 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) gained 61.6% to $4.75 after jumping around 56% on Friday.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) jumped 38% to $0.2644 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 37.8% to $0.6232 after gaining 11% on Friday.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) gained 34.4% to $12.25.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) jumped 26.8% to $14.76.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) jumped 24.2% to $0.4366.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) rose 23.5% to $2.9860.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) jumped 22.5% to $0.7936 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) gained 21.3% to $2.8862. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and announced a price target of $17.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares gained 19.8% to $4.1246 after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 19.3% to $0.5021. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) climbed 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.</li>
<li>PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) rose 18.4% to $4.19.</li>
<li>Cepton, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) jumped 18.4% to $2.9950 after the company announced it will be acquired by Koito for $3.17 per share in cash.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 17.2% to $2.25 after reporting preliminary second quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 16.1% to $15.35.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) jumped 13.7% to $79.76 after the company reported better-than-expected second quarter financial results.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) rose 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) gained 9.5% to $5.09.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 6.4% to $7.18. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) fell 34% to $1.5650 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dipped 31.4% to $14.55 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 28.6% to $0.1830 after gaining 6% on Friday.</li>
<li>Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) fell 26.4% to $14.90 following downbeat quarterly results.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) dipped 24.4% to $2.23. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 19.6% to $0.1536 after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) declined 18.5% to $8.84.</li>
<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) fell 17.5% to $0.2544.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 17% to $1.5243.</li>
<li>Integra Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#NYSE">ITRG</a>) fell 16.6% to $0.8999. Integra Resources and Florida Canyon Gold entered into a definitive arrangement agreement, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 16.6% to $3.3616. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 13.9% to $27.05 after the company lowered its FY24 guidance below estimates.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 12.8% to $14.01.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) fell 10.5% to $9.60.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) declined 10% to $7.24. Truist Securities analyst Jordan Levy maintained Sunnova Energy Intl with a Buy and raised the price target from $9 to $10.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $6.85. Mesoblast, last week, announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 6.3% to $139.61 after HSBC downgraded the stock from Hold to Reduce.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) fell 6.3% to $37.53.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40011559/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Intraday Update

Markets

Movers

AVXL

BMRC

CERO

CGTX

COMM

COUR

CPTN

CTRI

IART

ITRG

LIPO

LUXH

MESO

NIPG

NISN

NLSP

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

TIVC

TNDM

TWOU

VERO

VTVT

VTYX

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

On Sunday, Longeveron Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) presented Phase 2a clinical trial data and biomarker results at the Alzheimer&#8217;s Association <a href="https://www.benzinga.com/pressreleases/24/07/g40001948/longeveron-presents-study-results-from-clear-mind-phase-2a-clinical-trial-of-lomecel-b-in-mild-alz" target="_blank" rel="noreferrer noopener">International Conference (AAIC)</a>.
The Phase 2a CLEAR MIND trial evaluated 48 patients (36 were treated with Lomecel-B, and 12 received placebo).
The clinical trial achieved its primary safety and secondary efficacy endpoints, and the study results presented at AAIC 2024 support Lomecel-B&#8217;s therapeutic potential.
Key findings include:
<ul>
<li>The established safety profile of Lomecel-B for single and multiple dosing regimens was demonstrated in study data that showed no incidence of hypersensitivity, infusion-related reactions, and no cases of amyloid-related imaging abnormalities (ARIA).</li>
<li>Patients treated with Lomecel-B showed an overall slowing of disease worsening compared to placebo.</li>
<li>Efficacy results were demonstrated via a change from baseline at week 39 of the trial at prespecified levels using the Composite Alzheimer&#8217;s Disease Score (CADS), a secondary outcome measure that combines information across cognitive, functional capacity, and brain MRI domains.</li>
<li>Administration of Lomecel-B was associated with slowing cognitive and functional decline.</li>
<li>There was a statistically significant improvement relative to placebo observed in the Alzheimer&#8217;s Disease Cooperative Study Activities of Daily Living (ADCS-ADL).</li>
<li>Lomecel-B minimized the loss in brain volume in areas associated with Alzheimer&#8217;s Disease, statistically significant for left hippocampal volume relative to placebo. Along with positive changes in brain volumes, there was a 20-30% reduction in left and right ventricular enlargement, respectively.</li>
<li>Diffusion tensor imaging MRI supports the concept that Lomecel-B can potentially reduce neuroinflammation compared to placebo.</li>
</ul>
In October last year, Longeveron&nbsp;announced topline results from the Phase 2a trial of its investigational product Lomecel-B for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35106091/longeverons-alzheimers-candidate-meets-safety-goal-in-mid-stage-study" rel="noreferrer noopener">mild Alzheimer&#8217;s disease</a>.&nbsp;
The primary endpoint of safety was met based on statistical and medical assessment. One Serious Adverse Event (SAE) was reported on each Lomecel-B treatment group and none on placebo.&nbsp;
Earlier this month, the company announced that the&nbsp;FDA granted&nbsp;Regenerative Medicine Advanced Therapy (RMAT)&nbsp;designation to&nbsp;Lomecel-B for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39711667/why-is-longeveron-stock-soaring-on-wednesday" rel="noreferrer noopener">mild&nbsp;Alzheimer&#8217;s Disease</a>.
Price Action: LGVN stock is up 22.10% at $4.20 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992204/abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growt" target="_blank" rel="noreferrer noopener">AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations</a>.</li>
</ul>
Image via Shutterstock

Health Care

Why Is Alzheimer's-Focused Longeveron Stock Trading Higher On Monday?

LGVN: &nbsp;49% &#x7C; <a href="https://www.benzinga.com//node/40002230">Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Disease; Study Meets Its Key Objectives To Advance Data Supporting Favorable Benefit/Risk Profile</a>
&nbsp;
PHG: 11% &#x7C; <a href="https://www.benzinga.com//node/40003536">Koninklijke Philips Q2 2024 Adj EPS €0.30 Beats €0.25 Estimate, Sales €4.462B Beat €4.430B Estimate</a>
&nbsp;
LIPO: &nbsp;204% &#x7C; <a href="https://www.benzinga.com//node/40005335">Lipella Pharmaceuticals Commences Phase 2a Trial For LP-310 In Oral Lichen Planus, Enrolls First Patients</a>

Market-Moving News for July 29th

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Deutsche Bank increased Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) price target from $474 to $575. Deutsche Bank analyst Scott Deuschle upgraded the stock from Hold to Buy. Northrop Grumman shares gained 2.1% to close at $480.30 on Friday. <a href="https://www.benzinga.com/quote/NOC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut the price target for The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) from $80 to $64. Piper Sandler analyst Patrick Moley downgraded the stock from Overweight to Neutral. Charles Schwab shares gained 0.5% to close at $66.60 on Friday. <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Pivotal Research boosted the price target for Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from $400 to $435. Pivotal Research analyst Jeffrey Wlodarczak maintained a Buy rating. Charter Communications shares gained 16.6% to close at $367.62 on Friday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. boosted the price target for Texas Roadhouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) from $170 to $176. Stephens &amp; Co. analyst Jim Salera maintained an Equal-Weight rating. Texas Roadhouse shares rose 2% to close at $169.38 on Friday. <a href="https://www.benzinga.com/quote/TXRH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) price target from $48 to $57. Needham analyst James Ricchiuti maintained a Buy rating. Cognex shares rose 2% to close at $49.68 on Friday. <a href="https://www.benzinga.com/quote/CGNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut the price target for Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) from $12 to $10. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Longeveron shares rose 13.2% to close at $3.44 on Friday. <a href="https://www.benzinga.com/quote/LGVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>WestPark Capital cut Data I/O Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIO#NASDAQ">DAIO</a>) price target from $5 to $4. WestPark Capital analyst Kevin Garrigan maintained a Buy rating. Data I/O shares fell 4.3% to close at $2.67 on Friday. <a href="https://www.benzinga.com/quote/DAIO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) price target from $100 to $105. Keybanc analyst Justin Patterson maintained an Overweight rating. Trade Desk shares rose 1.7% to close at $92.43 on Friday. <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) price target from $490 to $515. Baird analyst Joel Beatty maintained an Outperform rating. argenx shares gained 1.7% to close at $494.46 on Friday. <a href="https://www.benzinga.com/quote/ARGX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt boosted Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) price target from $800 to $880. Rosenblatt analyst Hans Mosesmann maintained a Buy rating. Monolithic Power shares rose 4% to close at $821.78 on Friday. <a href="https://www.benzinga.com/quote/MPWR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40007546/anixa-biosciences-and-3-other-stocks-under-5-insiders-are-buying">Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying</a></li>
</ul>

ARGX

CGNX

CHTR

DAIO

MPWR

SCHW

TXRH

Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

WIIM

Longeveron shares are trading higher after the company announced study results from the CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer's disease, meeting its key objectives to advance data supporting a favorable benefit/risk profile.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and lowers the price target from $12 to $10.

HC Wainwright & Co. Maintains Buy on Longeveron, Lowers Price Target to $10

Shares of Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) shares rose sharply in today's pre-market trading following a report indicating that the company has sold a part of its <a href="https://www.benzinga.com/quote/PBI/news">e-commerce business to Stord</a>.
Pitney Bowes shares jumped 12.5% to $7.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) gained 46% to $3.45 in pre-market trading after the company announced that it will host an investor presentation to discuss results from its phase 2 SHINE study of CT1812 on Monday July 29, 2024.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares climbed 36.3% to $4.69 in pre-market trading after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) rose 35.7% to $3.99 in pre-market trading after jumping around 56% on Friday.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) shares gained 22.7% to $0.76 in pre-market trading after gaining 6% on Friday.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 22.1% to $0.5133 in pre-market trading. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 19.4% to $0.5395 in pre-market trading after gaining 11% on Friday.</li>
<li>Ambipar Emergency Response (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBI#NYSE">AMBI</a>) gained 15.5% to $5.34 in pre-market trading after jumping 29% on Friday.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares gained 14.1% to $0.3371 in pre-market trading. TransCode Therapeutics 13G filing showed 3i, LP reported a 9.9% stake in the company, as of July 23.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 11.4% to $7.51 in pre-market trading. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares fell 37.4% to $13.28 in pre-market trading after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined 34% to $0.1690 in pre-market trading after gaining 6% on Friday.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 22.1% to $0.1488 in pre-market trading after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 19.6% to $1.48 in pre-market trading.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares declined 13.1% to $0.63 in pre-market trading after surging 24% on Friday.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 12.6% to $3.53 in pre-market trading. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares fell 11.6% to $0.7250 in pre-market trading after jumping 11% on Friday.</li>
<li>NuZee Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) fell 9.7% to $3.40 in pre-market trading after surging around 25% on Friday.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) shares dipped 8.8% to $9.41 in pre-market trading.</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) shares fell 6.6% to $98.29 in pre-market trading. A jury ordered Abbott to pay $495 million in compensation and damages in a baby-formula verdict, the Wall Street Journal reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">&#8216;</a></li>
</ul>

Pre-Market Outlook

AMBI

EZPW

INVO

RNAZ

Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

- <a href="https://www.globenewswire.com/Tracker?data=SxjTJ9GbqAKx2VamE9fThROVzkBSRqkHmTmK8kNmNXqsrnPyRVeoJpKn01OfZx1VSf_YKuCtX58mrY_FtvmxHg==">Longeveron Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced that its positive Phase 2a clinical trial data and biomarker results were featured in two presentations, including a Featured Research Session oral presentation, at the Alzheimer&rsquo;s Association International Conference&reg; (AAIC), taking place July 28 &ndash; August 1, 2024, in Philadelphia and online.
&ldquo;As a medicinal signaling cell therapy that has multiple potential mechanisms of action to address inflammatory responses in the brain, Lomecel-B&trade; offers potential to address the underlying pathology of Alzheimer&rsquo;s Disease without the limitations of previous therapies,&rdquo; said <a href="https://www.globenewswire.com/Tracker?data=mbkW5AdmogKgnA5dwt3EzNTyciWePy-nGiRurR8Oy8VvLkxUulLO0XPNWYIKM6XiYk-l0LlE_AHlpneKQ5qgLm7gUe-hWQAmcRXcuEgKEhdcPxg8-OylakJffZNqj6gu">Wa&rsquo;el Hashad</a>, Chief Executive Officer at Longeveron. &ldquo;We are very encouraged by the safety profile and efficacy evidence that support the differentiated therapeutic potential of Lomecel-B&trade; and lay the foundation for its future clinical development. We&rsquo;re pleased to connect with the Alzheimer&rsquo;s community at AAIC 2024 and contribute to the growing body of evidence that fuels the continued development of novel therapeutics for this devastating disease.&rdquo;

Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Disease;  Study Meets Its Key Objectives To Advance Data Supporting Favorable Benefit/Risk Profile

Longeveron surges 14% on phase 2 Lomecel-B Alzheimer's data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept <a href="https://finance.yahoo.com/news/cognition-therapeutics-proof-concept-phase-110000080.html">Phase 2 &lsquo;SHINE&rsquo; study</a>.



This study evaluated the effectiveness of treating patients with CT1812. The results after six months were minor cognitive improvements across all categories compared to those taking a placebo.



This shows progress in slowing Alzheimer&rsquo;s&nbsp;disease effects by as much as 39%. However, it also didn&rsquo;t achieve statistical significance in a secondary endpoint for the 100mg and 300mg dose groups compared to placebo.



Lisa Ricciardi, president and CEO of Cognition Therapeutics, said the following about the clinical trial results.




&ldquo;We believe these results provide evidence that amyloid oligomer antagonism &ndash; a new and distinct mechanism for therapeutic intervention &ndash; may have a role as a monotherapy or in a combination with approved drugs for the treatment of AD and related dementias. In terms of percent improvement on evaluated cognitive measures, our results are comparable in magnitude to what was achieved with currently approved antibodies, with great ease of administration as a once daily dose, and less patient burden.&rdquo;




<h2>What&rsquo;s Next for CGTX Stock</h2>



Cognition Therapeutics has more catalysts on the horizon. That includes data from its Phase 2 Shimmer study set to come out later this year. It&rsquo;s also working on START trial for early-stage Alzheimer&rsquo;s disease and another Phase 2 proof-of-concept trial in dry AMD that&rsquo;s currently enrolling patients.



CGTX stock is down 32.5% as of Monday morning.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news that traders need to know about on Monday! Among that is what has shares of Abbott Labs&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/abt-stock-quote/">ABT</a>), Alibaba&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/baba-stock-quote/">BABA</a>) and Longeveron&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock on the move today. All of that info is ready at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/abbott-labs-abt-stock-falls-on-baby-formula-ruling-what-to-know/">Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.</a></li>



<li><a href="https://investorplace.com/2024/07/alibaba-baba-stock-rallies-on-higher-fees-why-investors-are-cheering/">Alibaba (BABA) Stock Rallies on Higher Fees. Why Investors Are Cheering.</a></li>



<li><a href="https://investorplace.com/2024/07/longeveron-lgvn-stock-pops-on-phase-2-trial-updates/">Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-cognition-therapeutics-cgtx-stock-down-33-today/">Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Small-cap stocks are back in favor. After languishing behind their larger brethren for years, <a href="https://investorplace.com/2024/07/small-caps-big-returns-3-dynamic-russell-2000-stocks-to-buy-in-july/">small-cap stocks are roaring ahead</a> as investors rotate into the sector once more.



The small-cap Russell 2000 <a href="https://www.marketwatch.com/investing/index/rut?mod=search_symbol">index is up 10%</a> in July versus the S&amp;P 500&rsquo;s flat performance and the tech-heavy Nasdaq 100 falling <a href="https://www.marketwatch.com/investing/index/ndx">close to 5%</a>. It was a reversal that was bound to happen and has been in preparation for a while.&nbsp;



<a href="https://investorplace.com/industries/technology/">Tech stocks</a> were the stars for the past two years as artificial intelligence mania gripped the market. Yet ahead of the hoped-for interest rate cuts in September, the frenzied growth of the sector did not seem sustainable.



Small-cap stocks, on the other hand, have been hardest hit by the <a href="https://investorplace.com/2024/07/top-small-cap-picks-3-unstoppable-russell-2000-stocks-to-buy-in-july/">Federal Reserve&rsquo;s monetary policies</a>. Because they are smaller, small-caps don&rsquo;t have the same access to money as larger companies do. That means debt borrowing is more expensive. Small-cap stock growth over the past two years was stunted because of it.



The S&amp;P 500 outpaced the Russell 2000 by more than 50% while the Nasdaq 100 easily more than doubled the small-cap index&rsquo;s performance. Now the tide is turning and these three small-cap stocks should be on your radar.



<h2>Longeveron (LGVN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/lgvn1600-300x169.png" alt="Female doctor holding virtual volumetric drawing of Heart in hand. Handrawn human organ, copy space on right side, grey hdr color. Healthcare hospital service concept stock photo. LGVN stock"><div>Source: mi_viri / Shutterstock.com</div></div>Clinical-stage biotech Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) seeks to treat age-related and life-threatening conditions. Its lead investigational drug Lomecel-B can treat a wide array of diseases but is in Phase 2b trials for treating a rare pediatric congenital heart birth defect called hypoplastic left heart syndrome (HLHS).&nbsp;



After completing an investigator meeting to <a href="https://investorplace.com/2024/06/3-penny-stocks-poised-to-turn-pocket-change-into-a-small-fortune-by-2028/">discuss the drug&rsquo;s progress</a> and operational implementation of the clinical trial, Longeveron stock tripled in value. Although it gave back much of those gains and remains down <a href="https://www.marketwatch.com/investing/stock/lgvn?mod=search_symbol">75%</a> for the year so far, there is an excellent chance Lomecel-B continues to advance.



Earlier this month the therapy was granted a regenerative medicine advanced therapy (RMAT) designation for treating Alzheimer&rsquo;s patients. Lomecel-B showed a slowing or prevention of the disease&rsquo;s worsening compared to a placebo. The RMAT designation is intended to speed up the development and review of regenerative medicine therapies.



Longeveron took the opportunity of its stock soaring to raise money by selling stock. And with shares still <a href="https://finance.yahoo.com/quote/LGVN/chart/#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--">300%</a> above their recent lows it may do so again to further bolster its balance sheet.



<h2>Netgear (NTGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/shutterstock_1586136250-300x169.jpg" alt="NTGR stock: Netgear logo on a sign at its Silicon Valley HQ."><div>Source: Michael Vi / Shutterstock</div></div>At one time, Netgear (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntgr-stock-quote/">NTGR</a>) was a top-notch networking equipment company. These days, it struggles along. Over the last five years the stock lost <a href="https://finance.yahoo.com/quote/NTGR/">53%</a> of its value but has lagged behind the Russell 2000 over just about any time period you look at. Over the past decade, where the small-cap stock index has doubled in value, NTGR stock <a href="https://finance.yahoo.com/quote/NTGR/chart/#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">lost 20%</a>.



Wall Street, though, is starting to <a href="https://finance.yahoo.com/news/compelling-long-raymond-james-bullish-124507626.html">sing a different tune</a> about Netgear. In an investor note, analysts at Raymond James recently said the company was &ldquo;forgotten about by investors and even the sell-side&rdquo; analysts.



According to Investing.com, the Windward Management hedge fund recently <a href="https://finance.yahoo.com/news/exclusive-activist-investor-sees-netgear-105754424.html">took a 4% stake</a> in the networking equipment maker. It believes Netgear&rsquo;s worst is behind it. The supply chain woes from the pandemic are behind it, it remains profitable on an EBITDA basis as it has for the past two decades and its shares are cheap, trading for around the cash it had in the bank at the time.



With the market essentially assigning it zero value, Netgear stands to gain as new management cleans out its inventories and its Netgear for Business segment remains strong. The stock is up <a href="https://finance.yahoo.com/quote/NTGR/chart/#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-">36%</a> since early May and if management heeds Windward&rsquo;s suggestion for a big stock buyback program, shares could run even higher.



<h2>Solid Power (SLDP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/sldp_solid_power_1600-300x169.png" alt="Smartphone with logo of American battery company Solid Power Inc. on screen in front of business website. Focus on center-left of phone display."><div>Source: T. Schneider / Shutterstock.com</div></div>Solid-state battery maker Solid Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sldp-stock-quote/">SLDP</a>) isn&rsquo;t in commercial production yet but is speeding development of its advanced cell designs. It is a highly speculative small-cap stock but one that could pay off long-term.



Part of the bull thesis behind Solid Power is the strong backing it is receiving from the automotive industry. Both Ford (NYSE:<a href="https://investorplace.com/stock-quotes/f-stock-quote/">F</a>) and BMW (OTCMKTS:<a href="https://investorplace.com/stock-quotes/bmwyy-stock-quote/">BMWYY</a>) are behind the company. It also has a deep partnership with SK On, the South Korean lithium-ion battery subsidiary of SK Innovation.



Solid Power installed a manufacturing line for SK On, which is licensing SLDP&rsquo;s design and technology. Solid Power also says it is on track to deliver to its partners its next-generation prototype A-2 cell for testing. As Solid Power meets its various milestones, it receives payments from its partners.



The first quarter saw such <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1844862/000110465924058007/tm2413485d1_8k.htm">payments rise by $2.2 million</a> to $6 million. It&rsquo;s not much but indicates Solid Power continues on the correct growth trajectory. At less than $2 per share, the solid-state battery maker will be volatile. That means investors should not dive whole hog into this small-cap stock. But as an investment for the speculative portion of your portfolio, Solid Power <a href="https://investorplace.com/2024/03/qs-stock-a-speculative-bet-on-an-uncertain-ev-battery-revolution/">could be one of numerous</a> solid-state battery makers to consider.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/the-top-3-small-cap-stocks-to-buy-now-summer-2024/">The Top 3 Small-Cap Stocks to Buy Now: Summer 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Top 3 Small-Cap Stocks to Buy Now: Summer 2024

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) just reported results for the second quarter of 2024.<ul><li>Longeveron reported earnings per share of -$1.83. This was below the analyst estimate for EPS of -$1.05.</li><li>The company reported revenue of $468,000.</li><li>This was 30% better than the analyst estimate for revenue of $360,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/lgvn-stock-earnings-longeveron-for-q2-of-2024/">LGVN Stock Earnings: Longeveron Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LGVN Stock Earnings: Longeveron Misses EPS, Beats Revenue for Q2 2024

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Longeveron (LGVN – Research Report), retaining the price target of $10.00. Ram ...

Buy Rating Reaffirmed for Longeveron on Strong Clinical Trial Prospects and Regulatory Advantages

Longeveron reports Q2 results

Catalyst Watch: Nvidia's blockbuster earnings, CrowdStrike on the hot seat, and PCE inflation watch

Wall Street Breakfast: The Week Ahead

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Longeveron (LGVN – Research Report) today and set a price target of $10.00. Ram Se...

Buy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial Progress

ADSK

AFRM

AVGO

BABA

CHUY

CHWY

CLOV

DELL

DIOD

DOMO

EXPE

FLUT

IBTA

LCID

LFUS

LULU

MRVL

NTGR

NUTX

NVMI

OKTA

PSTG

RDDT

SANA

SLDP

SMXT

TCOM

TELA

UBXG

ULTA

VRCA

WEST

WKHS

Press Releases

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Comments

Longeveron

Notizie

Ultime notizie per Longeveron (NASDAQ:LGVN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO